This top pharma stock has fallen too far.Dividend stocks are an important anchor for well-balanced portfolios. Regular cash distributions can buffer a portfolio against market volatility and provide a steady income across business cycles.Still, picking dividend stocks is no easy task. Companies operating in high-tech areas like healthcare often face unique competitive pressures that can diminish free cash flows, lowering their ability to reward shareholders via ever-larger dividend checks. Bristol Myers Squ ...

Bristol Myers Squibb (BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.The subcutaneous formulation of Opdivo is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all previously approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or i ...

Core Insights - NeoPhore Limited has secured additional funding from Bristol Myers Squibb to advance its research on the DNA mismatch repair (MMR) pathway in cancer and to progress its lead program towards candidate selection by 2025 [1][2]. Company Overview - NeoPhore is focused on developing small molecule drugs that target novel proteins within the MMR pathway, aiming to create next-generation immuno-oncology therapeutics to enhance clinical outcomes for cancer patients [2][3]. - The company was established as a spin-out from the University of Turin and PhoreMost Ltd, supported by the CRT Pioneer Fund [3]. Investment Details - The Series B extension round was oversubscribed, indicating strong investor interest and confidence in NeoPhore's approach [1][2]. - The funding will facilitate the completion of necessary pre-clinical studies for NeoPhore's lead PMS2 program [2]. Strategic Importance - The collaboration with Bristol Myers Squibb, a leader in the immuno-oncology field, is expected to bolster NeoPhore's position and accelerate its research efforts [2][4]. - NeoPhore's MMR inhibitors are designed to induce neoantigen expression, which enhances the immunogenicity of solid tumors, making them more responsive to immunotherapy [2].

Key PointsPerspective Therapeutics' major shareholder doubled down on the position, validating the business and pipeline. Liberty Live Group's SiriusXM stock is bought by Warren Buffett and Berkshire Hathaway. NB Bancorp is an aged institution that recently IPOd with great success; it is still undervalued. The threat of fines and imprisonment, up to twenty years for the worst offenders, makes insider trading a different game than what it was. Today, insiders must reveal their trading within days of executio ...

Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to the label expansion of chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The regulatory body approved Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approv ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life!Executing a capture-the-dividend trade entails buying the stock before the ex-date so you are the shareholder of record. You then sell it to book the dividend income, making little if any capital gains (that would be nice but it is not the objective). There are many factors to consider in buying dividend stocks for tactical traders.  The bigger the dividend the bigger the profi ...

Bristol-Myers Squibb Company. (NYSE:BMY) Guggenheim Securities Radiopharmaceuticals Day May 13, 2024 11:00 AM ET Company Participants Ben Hickey - President RayzeBio, Head of Mirati Conference Call Participants Unidentified Analyst Alright, Ben, let's continue here with Ben Hickey now from Bristol. Welcome. Thanks for joining us today. And so, yes, before we start with the fireside chat here, yes could you just introduce yourself and talk a bit about your role at Bristol. First of all, good to see you. Ben ...

Summary of Bristol-Myers Squibb Company Conference Call Company Overview - **Company**: Bristol-Myers Squibb Company (NYSE: BMY) - **Event**: Guggenheim Securities Radiopharmaceuticals Day - **Date**: May 13, 2024 Key Points Acquisition of RayzeBio - **Strategic Importance**: The acquisition of RayzeBio aligns with Bristol's focus on oncology, particularly in the radiotherapy space, which is seen as the next wave of cancer treatment [4][8] - **Operational Structure**: RayzeBio will operate as an independent entity within Bristol, allowing for agile decision-making akin to a biotech while leveraging Bristol's resources [6][4] - **Market Timing**: The acquisition was driven by the growing interest and potential in the radiotherapy market, making it an opportune moment for Bristol to enhance its capabilities [8] Technology and Product Development - **Actinium-225 Technology**: Bristol views actinium-based technology as superior due to its potency and ability to create double DNA strand breaks, which may lead to better patient outcomes [10][11] - **Clinical Trials**: The Phase 3 trial for RZY101 is designed as a post-lutetium study, with a focus on progression-free survival (PFS) as the primary endpoint [13][12] - **Safety Profile**: Early data indicates a favorable safety profile for RZY101, with minimal concerns regarding kidney accumulation [17] Pipeline and Future Opportunities - **Small Cell Lung Cancer**: RZY101 is being evaluated in combination with standard-of-care treatments, targeting a significant unmet need in this area [21][23] - **Hepatocellular Carcinoma (HCC)**: The GPC3 program aims to address the high unmet need in HCC, with plans to file an IND in the second half of 2024 [27][30] - **Expansion Plans**: Bristol is actively looking to expand its pipeline in radiotherapeutics, with a focus on both internal development and potential collaborations [39][40] Manufacturing and Supply Chain - **In-House Manufacturing**: Bristol has established a new facility in Indianapolis to ensure a reliable supply of actinium, addressing sourcing challenges in the market [33][32] - **Logistics Strategy**: The company is implementing systems for just-in-time delivery of therapies, leveraging its global footprint to meet patient needs efficiently [35] Financial Considerations - **Cost of Goods Sold (COGS)**: While specific guidance on COGS was not provided, it is expected to be within a similar range to existing lutetium-based programs, with potential for improvement as in-house capabilities expand [37] Conclusion - **Commitment to Oncology**: Bristol-Myers Squibb is positioning itself as a leader in the radiotherapy space, with a strong focus on innovation, strategic acquisitions, and expanding its clinical pipeline to address significant unmet medical needs in oncology [40][39]